Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

被引：33

作者：

Mailankody, Sham ^{[1
,2
]}

Liedtke, Michaela ^{[3
]}

Sidana, Surbhi ^{[4
]}

Matous, Jeffrey V. ^{[5
]}

Chhabra, Saurabh ^{[6
]}

Oluwole, Olalekan O. ^{[7
]}

Malik, Shahbaz A. ^{[8
]}

Kumar, Shaji ^{[9
]}

Nath, Rajneesh ^{[10
]}

Anwer, Faiz ^{[11
]}

Cruz, Jose Carlos ^{[12
]}

Jagannath, Sundar ^{[13
]}

Htut, Myo ^{[14
]}

Raje, Noopur S. ^{[15
]}

Siegel, David S. ^{[16
]}

Karski, Erin E. ^{[17
]}

Lovelace, Wade ^{[17
]}

Lourbakos, Afrodite ^{[17
]}

Nandakumar, Srinand Ponnathapura ^{[17
]}

Balakumaran, Arun ^{[17
]}

Hari, Parameswaran ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapeut Serv, New York, NY USA

[3] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[4] Stanford Univ Hosp, Div BMT & Cell Therapy, Stanford, CA 94305 USA

[5] Colorado Blood Canc Inst, Denver, CO USA

[6] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA

[7] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[8] St Davids South Austin Med Ctr, Bone Marrow Transplant & Cellular Therapy Program, Sarah Cannon Blood Canc Ctr, Austin, TX USA

[9] Mayo Clin, Rochester, MN USA

[10] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[11] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[12] Texas Transplant Inst, San Antonio, TX USA

[13] Mt Sinai Med Ctr, Dept Med Hematol & Med Oncol, New York, NY 10029 USA

[14] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA

[15] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA USA

[16] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[17] Allogene Therapeut, San Francisco, CA USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145572

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

651

引用

页数：5